District court hands Janssen a win in patent feud with Viatris
Johnson & Johnson’s Janssen has a new court win related to its antipsychotic drug.
A judge on Monday ruled that Mylan’s proposed labels for a generic version of paliperidone, Janssen’s antipsychotic drug, would infringe on one of Janssen’s patents, per an opinion and order filed in New Jersey District Court. (Mylan merged with Pfizer’s Upjohn unit in a deal that closed in late 2020 and is now called Viatris.)
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters